Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Robotic vs laparoscopic interval cytoreductive surgery in stage III ovarian cancer: an analysis of the National Cancer Database.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Frequency of lymph node involvement in clinically early-stage low-grade serous ovarian cancer: a systematic review and meta-analysis.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Unique Considerations in Rare Gynecologic Tumors: Gestational Trophoblastic Neoplasia, Germ Cell Tumors, and Clear Cell Ovarian Cancers.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Contemporary risk assessment and risk-reducing strategies for tubo-ovarian cancer in women with BRCA pathogenic variants.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Twin molar pregnancy: a diagnostic framework for early recognition and appropriate management.

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·2026
Same journal

Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.

Gynecologic oncology·2026
Same journal

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.

Gynecologic oncology·2026
Same journal

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same journal

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

Gynecologic oncology·2026
Same journal

A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.

Gynecologic oncology·2026
Same journal

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery?

Michael J Worley1, Stephanie H Guseh, J Alejandro Rauh-Hain

  • 1Division of Gynecologic Oncology, Brigham and Women's Hospital, Boston, MA, USA.

Gynecologic Oncology
|February 5, 2013
PubMed
Summary
This summary is machine-generated.

For elderly ovarian cancer patients, primary debulking surgery (PDS) shows similar survival outcomes to neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS). However, PDS significantly increases the risk of 30-day surgical readmission.

Related Experiment Videos

Last Updated: May 14, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Area of Science:

  • Gynecologic Oncology
  • Surgical Oncology
  • Geriatric Oncology

Background:

  • Ovarian, fallopian tube, and primary peritoneal carcinomas are aggressive malignancies.
  • Optimal surgical management for elderly patients (≥70 years) remains a critical consideration.
  • Treatment strategies include primary debulking surgery (PDS) and neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS).

Purpose of the Study:

  • To compare the efficacy and safety of PDS versus NACT-IDS in elderly patients with advanced ovarian/fallopian tube/primary peritoneal carcinoma.
  • To evaluate oncologic outcomes, including progression-free survival (PFS) and overall survival (OS).
  • To assess postoperative outcomes, such as length of stay (LOS) and readmission rates.

Main Methods:

  • Retrospective review of medical records for patients aged ≥70 years diagnosed between 2000 and 2010.
  • Stratification of patients into PDS and NACT-IDS groups.
  • Comparison of preoperative characteristics, surgical complexity, postoperative complications, and oncologic outcomes.

Main Results:

  • NACT-IDS was associated with less intraoperative blood loss, a higher rate of achieving no residual disease, and shorter hospital LOS.
  • Despite differences in surgical outcomes, PFS and OS were similar between the PDS and NACT-IDS groups.
  • Patients undergoing PDS had a significantly higher rate of 30-day readmission (17.6% vs. 2.5%).

Conclusions:

  • Primary debulking surgery (PDS) and NACT-IDS yield comparable oncologic outcomes for elderly patients with ovarian/fallopian tube/primary peritoneal carcinoma.
  • PDS is associated with a substantially increased risk of 30-day surgical readmission compared to NACT-IDS.
  • These findings suggest careful consideration of treatment strategies to minimize postoperative complications in this vulnerable patient population.